Literature DB >> 9361028

Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy.

E A Shoubridge1, T Johns, G Karpati.   

Abstract

Replicative segregation of mitochondrial DNA (mtDNA) can produce large differences in the proportions of wild-type and mutant mtDNAs in different cell types of patients with mitochondrial encephalomyopathy. This is particularly striking in the skeletal muscle of patients with Kearns-Sayre syndrome (KSS), a sporadic disease associated with large-scale mtDNA deletions, and in sporadic patients with tRNA point mutations. Although the skeletal muscle fibres of these patients invariably contain a large proportion of mutant mtDNAs, mutant mtDNAs are rare or undetectable in satellite cells cultured from the same muscle biopsy specimens. Since satellite cells are responsible for muscle fibre regeneration, restoration of the wild-type mtDNA genotype might be achieved in these patients by encouraging muscle regeneration. To test this concept, we re-biopsied a patient with a KSS phenotype and a mtDNA point mutation in the tRNAleu(CUN)gene and analysed muscle fibres regenerating at the site of the original muscle biopsy. Regenerating fibres were identified by morphological criteria and by expression of neural cell adhesion molecule (NCAM). All such fibers were positive for cytochrome c oxidase (COX) activity by cytochemistry and essentially homoplasmic for wild-type mtDNA, while the majority of non-regenerating fibres were COX-negative and contained predominantly mutant mtDNAs. These results demonstrate that it may be possible to improve muscle function in similar patients by methods that promote satellite cell incorporation into existing myofibres.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361028     DOI: 10.1093/hmg/6.13.2239

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  14 in total

Review 1.  Clinical mitochondrial genetics.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-06       Impact factor: 6.318

Review 2.  Altering the balance between healthy and mutated mitochondrial DNA.

Authors:  Paul M Smith; Robert N Lightowlers
Journal:  J Inherit Metab Dis       Date:  2010-05-27       Impact factor: 4.982

3.  Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease.

Authors:  Maria Pilar Bayona-Bafaluy; Bas Blits; Brendan J Battersby; Eric A Shoubridge; Carlos T Moraes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-22       Impact factor: 11.205

4.  Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model.

Authors:  S R Bacman; S L Williams; D Hernandez; C T Moraes
Journal:  Gene Ther       Date:  2007-06-28       Impact factor: 5.250

Review 5.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 6.  Therapies in inborn errors of oxidative metabolism.

Authors:  Manuel Schiff; Paule Bénit; Howard T Jacobs; Jerry Vockley; Pierre Rustin
Journal:  Trends Endocrinol Metab       Date:  2012-05-25       Impact factor: 12.015

7.  A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy.

Authors:  S Rahman; J W Taanman; J M Cooper; I Nelson; I Hargreaves; B Meunier; M G Hanna; J J García; R A Capaldi; B D Lake; J V Leonard; A H Schapira
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

8.  The use of mitochondria-targeted endonucleases to manipulate mtDNA.

Authors:  Sandra R Bacman; Sion L Williams; Milena Pinto; Carlos T Moraes
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

9.  Cytochrome c oxidase deficiency associated with the first stop-codon point mutation in human mtDNA.

Authors:  M G Hanna; I P Nelson; S Rahman; R J Lane; J Land; S Heales; M J Cooper; A H Schapira; J A Morgan-Hughes; N W Wood
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 10.  Current strategies towards therapeutic manipulation of mtDNA heteroplasmy.

Authors:  Claudia V Pereira; Carlos T Moraes
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.